Welcome! This Group has been assembled to exploit the content available in NextBio and the Community at-large to better understand mechanisms of breast cancer development and therapeutic options. Aimed at distinguishing clinical phenotypes and better treatment regimens, we use the various experimental data types, literature and clinical trials information available to us to explore, hypothesize, validate and share our knowledge. We use data derived from primary human tissue, as well as data from cell line and animal models.

Areas of interest to us include:

Clinical Phenotypes. Like Estrogen Receptor::ESR1 status, HER2::ERBB2 status, Progesterone Receptor::PGR status, double negative, triple negative, p53 status, BRCA1 status, lymph node, invasive, metastasis and recurrence/relapse status, Lobular, Ductal, Mucinous, Luminal, Stage and Grade.

Treatment Regimens. Like Hormonal, Chemotherapy and Radiation therapies. 5-fluorouracil, anastrozole, Bevacizumab,capecitabine, cisplatin, cyclophosphamide, denosumab, docetaxel, doxorubicin, endocrine disruptors, epirubicin, estradiol, exemestane, fulvestrant, gabapentin, gefitinib, goserelin, Herceptin, Lapatinib, letrozole, Paclitaxel, Resveratrol, tamoxifen, taxol, Tipifarnib, Tranilast, trastuzumab, vinorelbine, zoledronic acid

Causal and Sentinel Biomarkers. Like, ABCG2, ABL1, ADIPOQ, AKT1, ATM, AURKA, BCL2, beta-catenin, Bmnx, BMP2, BMP7, BRCA1, BRCA2, BRIP1, CASP8, CASR, CCND1, CD44, CDK10, CHEK2, COPS5, CTGF, CXCR4, CYP11A1, CYP19A1, EGFR, ERBB2, ERBB3, ESR1, ESR2, FGFR2, FOXP3, GAB2, IGF1R, IKBKE, IL6, MIRN21, MIRN410, MKI67, MMP9, MTA3, MTDH, MYC, NFKB1, NOTCH1, PALB2, PCGF2, PGR, PIK3CA, PIN1, prolactin, PTEN, PTPN1, RAD51, RHOC, SIRT1, SRC, STAT3, STN, TAC, TP53, ubiquitin, WISP2

Causal and Sentinel Pathways. Like, actin binding, angiogenesis, apoptosis, autophagy, basement membrane, bone mineral, cadherins, cell adhesion, cell cycle, cell cycle arrest, cell death, cell differentiation, cell growth, Cell killing, cell migration, cell motility, cell proliferation, cell surface, centrosome, chemokine receptor, chromatin, cyclin cyclin-dependent kinase inhibitor, cytochrome P450, dephosphorylation, DNA binding, DNA methylation, DNA repair, DNA replication, endocytosis, epithelial to mesenchymal transition, estrogen receptor binding, extracellular matrix, growth factor receptor, histone deacetylase, histone methylation, histone modifications, immune responses, intracellular kinase activity, Lipid rafts, lymphangiogenesis, microtubule nucleation, mutagenesis, Osteopontin, phosphorylation, protein stability, recombinational repair, RNA interference, signal transduction, transforming growth factor beta, vitamin D receptor, X chromosome

date founded:

June 2009

members:

28

membership:

open enrollment

categories: